Nov. 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on ...

It is driven by rising diabetes rates. The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market  size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of ...

Approved to treat diabetic gastroparesis, Gimoti is co-marketed with Eversana. Evoke underlined that nasal delivery provides ...

Evoke Pharma Inc (NASDAQ: EVOK) opened well over 100% up on Monday after reporting positive results for a study on its ...

Evoke Pharma Inc. (EVOK) and Eversana Life Science Services, LLC. announced statistically significant comparative data on its study ...

The study compared healthcare resource utilization of patients using Gimoti, a nasal formulation of the drug metoclopramide, versus oral metoclopramide, specifically focusing on individuals who ...

Evoke Pharma shares rose 70% on Monday after presenting data on Gimoti in GLP-1 users. Shares were trading around $9 in recent trading. The stock is down more than 28% on the year so far.

Despite the recent stock surge, Evoke Pharma’s year-to-date performance tells a different story. The stock is down a notable 57.44%, starkly contrasting with the S&P 500’s impressive 21.77% gain. This ...

Credit: Getty Images This patient fact sheet describes the medications that are known to induce tardive dyskinesia, its symptoms, and ways in which the disease state may be managed. Our easy-to ...